SCHEMBL2833712

SCHEMBL2833712

CCCNn1c(CN2CCCC2=O)c(C(=O)O)c2ccccc2c1=O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.42
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 3/20 0.37
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
CREBBP Q92793 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PER2 O15055 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
POLB P06746 1/20 0.36
METAP2 P50579 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834203 0.92 HTT (0.42) TSHRHTTL3MBTL1LMNAKMT2A
SCHEMBL2148839 0.85 L3MBTL1 (0.46) HTTL3MBTL1KMT2AKDM4ESMN1; SMN2
SCHEMBL2155047 0.85 TACR3 (0.43) TSHRKMT2ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL2834193 0.79 L3MBTL1 (0.44) TSHRHTTL3MBTL1LMNAKMT2A
SCHEMBL2831883 0.78 BDKRB1 (0.42) TSHRHTTL3MBTL1LMNAKMT2A
SCHEMBL2677165 0.78 L3MBTL1 (0.47) TSHRHTTL3MBTL1ALDH1A1HPGD
SCHEMBL2154227 0.77 TACR3 (0.44) TSHRKMT2ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL2832854 0.75 LMNA (0.40) TSHRHTTL3MBTL1LMNAKMT2A
SCHEMBL2148916 0.71 BDKRB1 (0.40) TSHRHTTL3MBTL1LMNAKMT2A
SCHEMBL2830636 0.71 CNR2 (0.38) TSHRL3MBTL1KMT2APER2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 TSHR 1316/4885HTT 636/4885L3MBTL1 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.